All In Biotech

Drug Trial Radar · NCT06845202

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

A Phase 1/2, Randomized, Double-blind, Placebo-controlled 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-4324 in Overweight to Obese Adult Healthy Volunteers and Multiple Dose ALN-4324 in Overweight to Obese Patients With Type 2 Diabetes Mellitus (T2DM)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

105

Actual

Start

Mar 3, 2025

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Feb 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM

Conditions

  • Obese or Overweight Healthy Volunteers
  • Type 2 Diabetes Mellitus (T2DM)

Interventions

  • ALN-4324Drug

    ALN-4324 will be administered subcutaneously (SC)

  • PlaceboDrug

    Placebo will be administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Frequency of Adverse Events (AEs)Time frame: Up to 9 months
  2. Part B: Frequency of Adverse EventsTime frame: Up to 12 months

Locations

22 sites in 6 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Montclair, California

  • Clinical Trial Site

    Washington D.C., District of Columbia

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Marlton, New Jersey

  • Clinical Trial Site

    Monroe, North Carolina

  • Clinical Trial Site

    Dallas, Texas

  • Clinical Trial Site

    Dallas, Texas

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    San Miguel de Tucumán, Argentina

  • Clinical Trial Site

    Concord, Canada

  • Clinical Trial Site

    Mount Royal, Canada

  • Clinical Trial Site

    Vancouver, Canada

  • Clinical Trial Site

    Santiago, Chile

  • Clinical Trial Site

    Santiago, Chile

  • Clinical Trial Site

    Santiago, Chile

  • Clinical Trial Site

    Essen, Germany

  • Clinical Trial Site

    Gdansk, Poland

  • Clinical Trial Site

    Tarnów, Poland

  • Clinical Trial Site

    Warsaw, Poland

  • Clinical Trial Site

    Wroclaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.